Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Esophageal Neoplasms

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Radiation: Radiation

First Posted Date: 2015-05-18

Last Posted Date: 2017-10-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 33

Registration Number: NCT02446574

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 3

Active, not recruiting

Conditions: Invasive Breast Carcinoma
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative
Stage II Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIC Breast Cancer
Estrogen Receptor Negative
Stage IIA Breast Cancer
Stage III Breast Cancer

Interventions: Drug: Carboplatin
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2015-05-15

Last Posted Date: 2024-07-03

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 415

Registration Number: NCT02445391

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 1014 locations

A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: endostar
Radiation: intensity modulated radiation
Drug: cisplatin

First Posted Date: 2015-05-15

Last Posted Date: 2020-06-24

Lead Sponsor: China Three Gorges University, Yichang, China

Target Recruit Count: 75

Registration Number: NCT02444949

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Gemcitabine
Drug: Dexamethasone
Drug: Mesna
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Selinexor
Drug: G-CSF

First Posted Date: 2015-05-07

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 320

Registration Number: NCT02436707

Locations: 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 11 locations

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 2

Conditions: Ovarian Epithelial Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: p53 gene
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2015-05-06

Last Posted Date: 2015-05-06

Lead Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Target Recruit Count: 100

Registration Number: NCT02435186

Locations: 🇨🇳
xijing hospital in China Medical University, Shenyang, Liaoning, China

Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Docetaxel,Cisplatin,Fluorouracil
Radiation: Intensity-modulated radiation therapy (IMRT)
Drug: Cisplatin

First Posted Date: 2015-05-05

Last Posted Date: 2018-05-16

Lead Sponsor: Wei Jiang

Target Recruit Count: 440

Registration Number: NCT02434614

Locations: 🇨🇳
Guigang People's Hospital, Guigang, Guangxi, China
🇨🇳
Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
🇨🇳
Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China

and more 3 locations

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

Phase 1

Conditions: Lung Cancer
Endometrial Cancer
Cervical Cancer
HNSCC
Pancreatic Cancer
Fallopian Tube Cancer
Colorectal Cancer
Head and Neck Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Drug: COTI2
Drug: Cisplatin

First Posted Date: 2015-05-05

Last Posted Date: 2019-02-01

Lead Sponsor: Critical Outcome Technologies Inc.

Target Recruit Count: 51

Registration Number: NCT02433626

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: paclitaxel
Drug: cisplatin
Procedure: Radical hysterectomy and bilateral pelvic lymphadenectomy

First Posted Date: 2015-05-04

Last Posted Date: 2017-10-30

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 64

Registration Number: NCT02432365

Locations: 🇨🇳
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan
🇨🇳
Department of Obstetrics & Gynecology, Chang Gung Memorial Hospital, Taipei, Taiwan
🇨🇳
Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Phase 3

Recruiting

Conditions: Ovarian Germ Cell Cancer
Ovarian Neoplasms
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bleomycin
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2023-04-25

Lead Sponsor: Beihua Kong

Target Recruit Count: 129

Registration Number: NCT02429687

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Phase 3

Recruiting

Conditions: Ovarian Sex Cord Stromal Tumor
Ovarian Neoplasms
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bleomycin
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2023-04-25

Lead Sponsor: Beihua Kong

Target Recruit Count: 132

Registration Number: NCT02429700

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy